Skip to main content

handshake-agreement-121117-pixa.png

Analysts had forecast a blockbuster year for life science mergers and acquisitions as the lower tax rate for repatriated cash kicks-in and Big Pharma continues its hunt for late-stage assets.

{iframe}https://medcitynews.com/2018/01/anatomy-two-biotech-deals-worth-20b/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=60154561&_hsenc=p2ANqtz-8PELItGR-LuafbyKTAX63Y7tMOWz3wuqzXai53xOL98QsyMCDpsnD2eH8vIOeWzdQX5AKZPPr3Gsr2mSMEjLmL7fKNsQ&_hsmi=60154561{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.